The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
 
Giannis Mountzios
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; F. Hoffmann LaRoche; Gilead Sciences; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Summit Therapeutics
Speakers' Bureau - Takeda
Expert Testimony - Amgen; AstraZeneca; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Sharp & Dohme
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - J INTS BIO; KANAPH Therapeutics Inc.
Consulting or Advisory Role - Cyrus therapeutixs; J Ints Bio; KANAPH Theripeutic Inc
Speakers' Bureau - ASCO; AstraZeneca/MedImmune; ESMO; Guardant Health; IASLC; Korean Cancer Association; Korean Cancer Study Group; Korean Society of Medical Onoclogy; Korean Society of Thyroid-Head and Neck Surgery; MSD; Novartis; Pfizer; Roche; The Chinese Thoracic Oncology Society; Zai Lab
Research Funding - CJ bioscience; Cyrus Therapeutics; Dong-A ST; ImmuneOncia; J Ints Bio; Johnson & Johnson; Ligachem bioscience; MSD; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Phil Lammers
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb/Sanofi; Daiichi Sankyo/Astra Zeneca; Genzyme; Merck; Pfizer; Puma Biotechnology; Tempus; Teva
Speakers' Bureau - Amgen; AstraZeneca
 
Longhua Sun
No Relationships to Disclose
 
Surein Arulananda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Johnson & Johnson; Merck Sharp & Dohme; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
 
Fiona Blackhall
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim
 
Tatsuya Yoshida
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Genexine; Merck Serono; MSD; Pfizer; TAKEDA; Voronoi Health Analytics; YUHAN
 
Salman Punekar
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Neogene Therapeutics (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
Travel, Accommodations, Expenses - Revolution Medicines
 
Bo Zhu
No Relationships to Disclose
 
Tudor-Eliade Ciuleanu
Consulting or Advisory Role - A&D Pharma; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MagnaPharm; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; SERVIER; Takeda
Travel, Accommodations, Expenses - A&D Pharma; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Servier
 
Julien Mazieres
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Pfizer; Pierre Fabre; Revolution Medicines; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; MSD; Pfizer
 
Antonio Lugini
No Relationships to Disclose
 
Pedro Rocha
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Kyowa Kirin; Merck Sharp & Dohme; PharmaMar; Roche
 
Ippokratis Korantzis
No Relationships to Disclose
 
Martin Schuler
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson/Janssen; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunocore; Johnson & Johnson/Janssen; MSD; Novartis; Regeneron; Roche; Sanofi; Tacalyx
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Wei Shi
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Ali Hamidi
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Diana Gauto
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Charles Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Jazz Pharmaceuticals; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Royalties related to licensing of anti-DLL3 antibodies.